...
首页> 外文期刊>Vaccine >Evaluation of the purity of a purified, inactivated hepatitis A vaccine(VAQTA (TM))
【24h】

Evaluation of the purity of a purified, inactivated hepatitis A vaccine(VAQTA (TM))

机译:评估纯化的灭活甲型肝炎疫苗(VAQTA(TM))的纯度

获取原文
获取原文并翻译 | 示例
           

摘要

Manufacture of VAQTA(TM), an inactivated hepatitis A virus vaccine, includes extensive purification of the intact virus particle to remove endogenous components from the host cell culture lysate as well as compounds introduced in the upstream purification process. Analysis of the final purified hepatitis A virus product by SDS-PAGE prior to inactivation shows that greater than 95% of the protein in the preparation is found in four protein bands, which have been confirmed to be hepatitis A virus capsid proteins VP0. VP1, VP2 and VP3 based on Western blot and mass spectrometry analyses. Validation of the manufacturing process and direct analysis of the final product were used to demonstrate that no other specific host cell-derived components are detected and that process residuals are all below the limits of detection of the assays used. Establishment of a rigorous standard of high purity for this product was pursued to minimize the impact of impurities during clinical development of this product and will facilitate the incorporation of this product into combination vaccines. (C) 1999 Elsevier Science Ltd. All rights reserved. [References: 15]
机译:灭活的甲型肝炎病毒疫苗VAQTA™的制造包括完整病毒颗粒的广泛纯化,以从宿主细胞培养物裂解物中除去内源性成分,以及在上游纯化过程中引入的化合物。灭活前通过SDS-PAGE分析最终纯化的甲型肝炎病毒的最终产物表明,制剂中超过95%的蛋白质存在于四个蛋白带中,这些蛋白带已被确认为甲肝病毒衣壳蛋白VP0。基于蛋白质印迹和质谱分析的VP1,VP2和VP3。制造过程的验证和最终产品的直接分析用于证明未检测到其他任何特定的宿主细胞衍生成分,并且过程残留均低于所用检测方法的检测极限。一直在为该产品建立严格的高纯度标准,以最大程度地减少该产品临床开发过程中杂质的影响,并有助于将该产品掺入联合疫苗中。 (C)1999 Elsevier ScienceLtd。保留所有权利。 [参考:15]

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号